Monitoring oligomer formation from self-aggregating amylin peptides using ESI-IMS-MS

International Journal for Ion Mobility Spectrometry

Volumn 16, Issue 1, 2013, Pages 29-39

  Young, Lydia ^a   Ndlovu, Hlengisizwe ^a   Knapman, Tom W ^a,b   Harris, Sarah A ^a   Radford, Sheena E ^a   Ashcroft, Alison E ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b MDS SCIEX   (Canada)

Author keywords

Amyloid; Fibril; Ion mobility spectrometry mass spectrometry; Islet amyloid polypeptide; Molecular modelling

Indexed keywords

DIMERS; ELECTROSPRAY IONIZATION; GLYCOPROTEINS; ION MOBILITY SPECTROMETERS; MASS SPECTROMETRY; MOLECULAR MODELING;

AMYLOID; CROSS SECTIONAL AREA; ELECTROSPRAY IONIZATION MASS SPECTROMETRY; FIBRIL; FIBRILLAR STRUCTURES; ION MOBILITY SPECTROMETRY; ISLET AMYLOID POLYPEPTIDES; MECHANISM OF FORMATION;

PEPTIDES;

EID: 84874522949     PISSN: 14356163     EISSN: 18654584     Source Type: Journal    
DOI: 10.1007/s12127-012-0115-z     Document Type: Article

References (59)

1. Hoaglund CS, Valentine SJ, Sporleder CR, Reilly JP, Clemmer DE (1998) Three-dimensional ion mobility/TOFMS analysis of electrosprayed biomolecules. Anal Chem 70: 2236-2242.
2. Pringle SD, Giles K, Wildgoose JL, Williams JP, Slade SE, Thalassinos K, Bateman RH, Bowers MT, Scrivens JH (2007) An investigation of the mobility separation of some peptide and protein ions using a new hybrid quadrupole/travelling wave IMS/oa-ToF instrument. Int J Mass Spectrom 261: 1-12.
3. Kemper PR, Dupuis NF, Bowers MT (2009) A new, higher resolution, ion mobility mass spectrometer. Int J Mass Spectrom 287: 46-57.
4. Shepherd DA, Veesler D, Lichiere J, Ashcroft AE, Cambillau C (2011) Unraveling lactococcal phage baseplate assembly by mass spectrometry. Mol Cell Proteomics 10: M111. 0009787.
5. Uetrecht C, Versluis C, Watts NR, Wingfield PT, Steven AC, Heck AJ (2008) Stability and shape of hepatitis B virus capsids in vacuo. Angew Chem Int Ed Engl 47: 6247-6251.
6. Ashcroft AE (2005) Recent developments in electrospray ionisation mass spectrometry: noncovalently bound protein complexes. Nat Prod Rep 22: 452-464.
7. Zhou M, Morgner N, Barrera NP, Politis A, Isaacson SC, Matak-Vinkovic D, Murata T, Bernal RA, Stock D, Robinson CV (2011) Mass spectrometry of intact V-type ATPases reveals bound lipids and the effects of nucleotide binding. Science 334: 380-385.
8. Benesch JL, Ruotolo BT, Simmons DA, Robinson CV (2007) Protein complexes in the gas phase: technology for structural genomics and proteomics. Chem Rev 107: 3544-3567.
9. Bich C, Zenobi R (2009) Mass spectrometry of large complexes. Curr Opin Chem Biol 19: 632-639.
10. Heck AJ (2008) Native mass spectrometry: a bridge between interactomics and structural biology. Nat Methods 11: 927-933.
11. Loo JA (1997) Studying noncovalent protein complexes by electrospray ionization mass spectrometry. Mass Spectrom Rev 16: 1-23.
12. Smith DP, Radford SE, Ashcroft AE (2010) Elongated oligomers in beta2-microglobulin amyloid assembly revealed by ion mobility spectrometry-mass spectrometry. Proc Natl Acad Sci USA 107: 6794-6798.
13. Bernstein SL, Dupuis NF, Laz ND, Wyttenbach T, Condron MM, Bitan G, Teplow BD, Shea J, Ruotolo BT, Robinson CV, Bowers MT (2009) Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nat Chem 1: 326-331.
14. Kloniecki M, Jablonowska A, Poznanski J, Langridge J, Hughes C, Campuzano I, Giles K, Dadlez M (2011) Ion mobility separation coupled with MS detects two structural states of Alzheimer's disease Aβ1-40 peptide oligomers. J Mol Biol 407: 110-124.
15. Ashcroft AE (2010) Mass spectrometry and the amyloid problem-how far can we go in the gas phase? J Am Soc Mass Spectrom 21: 1087-1096.
16. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P (2010) Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the international society of amyloidosis. Amyloid 17: 101-104.
17. Shewmaker F, McGlinchey RP, Wickner RB (2011) Structural insights into functional and pathological amyloid. J Biol Chem 286: 16533-16540.
18. Ross CA, Poirier MA (2004) Protein aggregation and neurodegenerative disease. Nat Methods 10: 10-17.
19. Chiti F, Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Ann Rev Biochem 75: 333-366.
20. Caughey B, Lansbury PT (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Ann Rev Neurosci 26: 267-298.
21. Last NB, Rhoades E, Miranker AD (2011) Islet amyloid polypeptide demonstrates a persistent capacity to disrupt membrane integrity. Proc Natl Acad Sci USA 108: 9460-9465.
22. Smith DP, Woods LA, Radford SE, Ashcroft AE (2011) Structure and dynamics of oligomeric intermediates in β2-microglobulin self-assembly. Biophys J 101: 1238-1247.
23. Bernstein SL, Liu D, Wyttenbach T, Bowers MT, Lee JC, Gray HB, Winkler JR (2004) Alpha-synuclein: stable compact and extended monomeric structures and pH dependence of dimer formation. J Am Soc Mass Spectrom 15: 1435-1443.
24. Dupuis NF, Wu C, Shea J-E, Bowers MT (2009) Human islet amyloid polypeptide monomers form ordered β-hairpins: a possible direct amyloidogenic precursor. J Am Chem Soc 131: 18283-18292.
25. Dupuis NF, Wu C, Shea JE, Bowers MT (2011) The amyloid formation mechanism in human IAPP: dimers have β-strand monomer-monomer interfaces. J Am Chem Soc 133: 7240-7243.
26. Grabenauer M, Wu C, Soto P, Shea JE, Bowers MT (2009) Oligomers of the prion protein fragment 106-126 are likely assembled from β-hairpins in solution, and methionine oxidation inhibits assembly without altering the peptide's monomeric conformation. J Am Chem Soc 132: 532-539.
27. Stridsberg M, Wilander E (1991) Islet amyloid polypeptide (IAPP). A short review. Acta Oncol 30: 451-456.
28. Westermark P, Andersson A, Westermark GT (2011) Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev 91: 795-826.
29. Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C (1990) Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 87: 5036-5040.
30. Larson JL, Ko E, Miranker AD (2000) Direct measurement of islet amyloid polypeptide fibrillogenesis by mass spectrometry. Prot Sci 9: 427-431.
31. Zhao J, Yu X, Liang G, Zheng J (2011) Heterogeneous triangular structures of human islet amyloid polypeptide (amylin) with internal hydrophobic cavity and external wrapping morphology reveal the polymorphic nature of amyloid fibrils. Biomacromolecules 12: 1781-1784.
32. Tenidis K, Waldner M, Bernhagen J, Fischle W, Bergmann M, Weber M, Merkle ML, Voelter W, Brunner H, Kapurniotu A (2000) Identification of a penta- and hexapeptide of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties. J Mol Biol 295: 1055-1071.
33. Moriarty DF, Raleigh DP (1999) Effects of sequential proline substitutions on amyloid formation by human amylin 20-29. Biochemistry 38: 1811-1818.
34. Glenner GG, Eanes D, Wiley C (1988) Amyloid fibrils formed from a segment of the pancreatic islet amyloid protein. Biochem Biophys Res Commun 155: 608-614.
35. Giles K, Pringle SD, Worthington KR, Little D, Wildgoose JL, Bateman RH (2004) Applications of a travelling wave-based radio-frequency-only stacked ring ion guide. Rapid Commun Mass Spectrom 18: 2401-2414.
36. Smith DP, Knapman TW, Campuzano I, Malham RW, Berryman JT, Radford SE, Ashcroft AE (2009) Deciphering drift time measurements from travelling wave ion mobility spectrometry-mass spectrometry studies. Eur J Mass Spectrom 15: 113-130.
37. Valentine SJ, Counterman AE, Clemmer DE (1999) A database of 660 peptide ion cross sections: use of intrinsic size parameters for bona fide predictions of cross sections. J Am Soc Mass Spectrom 10: 1188-1211.
38. Platt GW, Routledge KE, Homans SW, Radford SE (2008) Fibril growth kinetics reveal a region of beta 2-microglobulin important for nucleation and elongation of aggregation. J Mol Biol 378: 251-263.
39. Madine J, Jack E, Stockley PG, Radford SE, Serpell LC, Middleton DA (2008) Structural insights into the polymorphism of amyloid-like fibrils formed by region 20-29 of amylin revealed by solid-state NMR and x-ray fiber diffraction. J Am Chem Soc 130: 14990-15001.
40. Middleton DA (2011) Solid-state NMR detection of 14N-13C dipolar couplings between amino acid side groups provides constraints on amyloid fibril architecture. Magn Reson Chem 49: 65-69.
41. Macke T, Case DA (1998) Modelling unusual nucleic acid structures. In: Leontes NB, SantaLucia J Jr (eds) Molecular modelling of nucleic acids. American Chemical Society, Washington, DC, pp 379-393.
42. Case DA, Cheatham TE, Darden TA, Gohlke H, Luo R, Merz KM, Onufriev C, Simmerling C, Wang B, Woods RJ (2005) The amber biomolecular simulation programs. J Comput Chem 26: 1668-1688.
43. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kale L, Schulten K (2005) Scalable molecular dynamics with NAMD. J Comput Chem 36: 1781-1802.
44. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C (2006) Comparison of multiple amber force fields and development of improved backbone parameters. Proteins 65: 712-725.
45. Mesleh MF, Hunter JM, Shvartsburg AA, Schatz GC, Jarrold MF (1996) Structural information from ion mobility measurements: effects of the long-range potential. J Phys Chem 100: 16082-16086.
46. Ashburn TT, Lansbury PT (1993) Interspecies variations affect the kinetics and thermodynamics of amyloid plaque formation; peptide models of pancreatic amyloid. J Am Chem Soc 115: 11012-11013.
47. Wiltzius JJW, Sievers SA, Sawaya MR, Cascio D, Popov D, Riekel C, Eisenberg D (2008) Atomic structure of the cross-beta spine of uslet amyloid polypeptide (amylin). Prot Sci 17: 1467-1474.
48. Ruotolo BT, Benesch JL, Sandercock AM, Hyung SJ, Robinson CV (2008) Ion mobility-mass spectrometry analysis of large protein complexes. Nat Protoc 3: 1139-1152.
49. Bleiholder C, Dupuis NF, Wyttenback T, Bowers MT (2011) Ion mobility-mass spectrometry reveals a conformational conversion from random assembly to β-sheet in amyloid fibril formation. Nat Chem 3: 172-177.
50. Nielsen JT, Bjerring M, Jeppesen MD, Pedersen RO, Pedersen JM, Hein KL, Vosegaard T, Skrydstrup T, Otzen DE, Nielsen NC (2009) Unique identification of supramolecular structures in amyloid fibrils by solid-state NMR spectroscopy. Angew Chem Int Ed Engl 48: 2118-2121.
51. Straaso LA, Nielsen NC (2010) Recoupling of native homonuclear dipolar couplings in magic-angle-spinning solid-state NMR by the double-oscillating field technique. J Chem Phys 133: 064501.
52. Smith AM, Jahn TR, Ashcroft AE, Radford SE (2006) Direct observation of oligomeric species formed in the early stages of amyloid fibril formation using electrospray ionisation mass spectrometry. J Mol Biol 364: 9-19.
53. World Health Organisation (2012) http://www. who. int/features/factfiles/diabetes. Accessed 6 Nov 2012.
54. Hoppener JWM, Nieuwenhuis MG, Vroom TM, Ahren B, Lips CJM (2002) Role of islet amyloid in type 2 diabetes mellitus: consequence or cause? Mol Cell Endocrinol 197: 205-212.
55. Cao P, Raleigh DP (2012) Analysis of the inhibition and remodeling of islet amyloid polypeptide amyloid fibers by flavanols. Biochemistry 51: 2670-2683.
56. Cheng B, Gong H, Li X, Sun Y, Zhang X, Chen H, Liu X, Zheng L, Huang K (2012) Silibinin inhibits the toxic aggregation of human islet amyloid polypeptide. Biochem Biophys Res Commun 419: 495-499.
57. Cheng B, Liu X, Gong H, Huang L, Chen H, Zhang X, Li C, Yang M, Ma B, Jiao L, Zheng L, Huang K (2011) Coffee components inhibit amyloid formation of human islet amyloid polypeptide in vitro: possible link between coffee consumption and diabetes mellitus. J Agric Food Chem 59: 13147-13155.
58. Trikha S, Jeremic AM, Zraika S, Hull RL, Verchere CB, Clark A, Potter KJ, Fraser PE, Raleigh DP, Khan SE (2011) Clustering and internalization of toxic amylin oligomers in pancreatic cells require plasma membrane cholesterol. J Biol Chem 286: 36086-36097.
59. Zraika S, Hull RL, Verchere CB, Clark A, Potter KJ, Fraser PE, Raleigh DP, Kahn SE (2010) Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence? Diabetologia 53: 1046-1056.